Citations

Clear

124 citation(s) found for "Storm, A".

EUS-guided gallbladder drainage vs dual stent transpapillary gallbladder drainage for management of acute cholecystitis
Amin, Dhruval , Rau, Prashanth , Cooper, Katherine M. , Sayegh, Lea N. , Mostafa, Nouran, Achebe, Ikechukwu , DeVore, Zachary, Gonzalez, Daniella, Stephanie, Stephanie , Mehta, Savant, Marshall, Christopher , Nasser‐Ghodsi, Navine , Marya, Neil B. , Cooper, Katherine M , Sayegh, Lea Nicole , Storm, Andrew C , Mostafa, Nouran, Zivny, Jaroslav, Storm, Andrew C. , Marya, Neil B.

Mayo Clinic

Endoscopy International Open | January 2, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2509-7076 | PMID 40007656 Get It

Abstract Cholecystectomy (CCY) is the standard treatment for acute cholecystitis. For non-surgical patients, percutaneous cholecystostomy tube (PT-GBD) is recommended but is associated with high readmission rates and poor quality of life. Endoscopic gallbladder decompression techniques, including endoscopic transpapillary gallbladder drainage (ET-GBD) and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD), are alternatives. Studies comparing ET-GBD and EUS-GBD have shown EUS-GBD to have superior outcomes. However, these studies assessed ET-GBD mostly via single transcystic stent placement (SSET-GBD). This study aimed to compare outcomes of dual transcystic stents (DSET-GBD) and EUS-GBD in non-surgical candidates with acute cholecystitis. A multicenter analysis was conducted on patients who underwent ET-GBD or EUS-GBD between January 2019 and January 2023. Data were extracted from electronic medical records and outcomes including technical success, success, adverse events (AEs), and recurrence rates of cholecystitis were measured. Of 129 procedures (56 EUS-GBD; 73 ET-GBD), technical success was achieved in 87.5% of EUS-GBD and 86.3% of ET-GBD attempts. Immediate clinical success was achieved in 98.1% for EUS-GBD and 100% for DSET-GBD. AE rates were similar between the groups. Recurrent cholecystitis rates were 5.3% for EUS-GBD and 8.2% for DSET-GBD (P = 0.692). This study demonstrates that DSET-GBD has similarly low rates of recurrent acute cholecystitis compared with EUS-GBD. DSET-GBD should be considered as an alternative management strategy for management of acute cholecystitis in patients who are unable to undergo CCY.
Comparative effectiveness of Roux‐en‐Y gastric bypass and sleeve gastrectomy in achieving diabetes remission in patients with diabetes‐related vascular diseases: A multicentred study
Ghusn, Wissam , Ma, Pearl , Ikemiya, Kayla , Salame, Marita , Kendrick, Michael, Higa, Kelvin , Hage, Karl , Mosleh, Kamal Abi , Storm, Andrew C. , Dayyeh, Barham K. Abu , Ghanem, Omar M.

Mayo Clinic

Clinical Obesity | December 21, 2024 | Volume: 15 | Issue: 3 | Pages: No page available

10.1111/cob.12732 | PMID 39707819 Get It

Summary Metabolic and bariatric surgeries (MBS), including Roux‐en‐Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG), have proven effective in promoting long‐term diabetes remission among patients with type‐2 diabetes (T2D). In this multicentre retrospective cohort study, we investigated the effectiveness of RYGB and SG in achieving diabetes remission, specifically among patients with T2D and vascular complications, while accounting for similar baseline diabetes severity. Although various scores predict diabetes remission after bariatric surgery, they do not consider diabetes‐related vascular complications, which can influence outcomes even in patients with similar baseline T2D severity. We collected preoperative data on microvascular (retinopathy, nephropathy, neuropathy) and macrovascular comorbidities (coronary artery disease, cerebrovascular accidents, peripheral artery disease) to compare the efficacy of RYGB and SG. Among 961 patients analysed, those with vascular complications showed higher remission rates with RYGB (OR: 1.97) compared to SG, despite similar baseline diabetes severity. Notably, RYGB patients with microvascular complications had a significant advantage in achieving T2D remission (OR: 2.95). However, no significant differences in remission were observed in patients with macrovascular complications. These findings suggest that RYGB may be more effective than SG in specific patient populations, particularly those with microvascular complications, emphasizing the need for personalized treatment strategies.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
Mendez, Joe , Cohen, Adam L. , Eckenstein, Midori, Jensen, Randy L. , Burt, Lindsay , Salzman, Karen L. , Chamberlain, Marc C. , Hsu, Henry H. , Hutchinson, Marguerite, Mrugała, Maciej M. , Pelayo, Michael, Raizer, Jeffrey J. , Reardon, David A. , Sterba, Michael, Walbert, Tobias , Wong, Eric T. , Zhang, Chao , Colman, Howard , Mendez, Joe S , Reardon, David A , Walbert, Tobias , Colman, Howard , IWAMOTO, FABIO MASSAITI , Ligon, Keith L , Plotkin, Scott R. , Puduvalli, Vinay K. , West, Brian L.

Mayo Clinic

Neuro-Oncology Advances | November 19, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdae202 | PMID 39734810 Get It

Abstract Background Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance. We added pexidartinib to standard-of-care RT/temozolomide (TMZ) in patients with newly diagnosed GBM to assess the therapeutic benefit of altering the tumor microenvironment with pexidartinib. Methods In this open-label, dose-escalation, multicenter, Phase 1b/2 trial, pexidartinib was administered in combination with RT/TMZ followed by adjuvant pexidartinib + TMZ. During Phase 1b, pexidartinib was given 5 or 7 days/week at multiple dosing levels. The primary Phase 1b endpoint was the recommended Phase 2 dose (RP2D). Phase 2 patients received the RP2D with the primary endpoint of median progression-free survival (mPFS). Secondary objectives were median overall survival (mOS), pharmacokinetics, and safety. Results The RP2D of pexidartinib was 800 mg/day for 5 days/week during RT/TMZ, followed by 800 mg/day for 7 days/week with adjuvant TMZ. mPFS was 6.7 months (90% CI: 4.5, 11.5) for the modified intention-to-treat population. The actual mOS was 13.1 months (90% CI: 11.5, 24.5), and the mOS corrected for comparison with matched historical controls was 18.8 months (95% CI: 12.6, 28.0). Conclusions This trial established the RP2D of pexidartinib in combination with RT/TMZ and adjuvant TMZ. Pexidartinib was generally safe and well tolerated. Although the study regimen with pexidartinib was not efficacious, pharmacodynamic studies showed modulation of systemic markers that could lead to alteration of the tumor microenvironment.
S136 Obesity Is Associated With Worsened Endoscopic Outcomes in Patients With Pancreatic Collections and Should Be Integrated Into the QNI Classification
Baroud, Serge , Annan, Karim Al , Mrad, Rudy , Han, Sam , Law, Ryan , Bofill-García, Aliana, Martin, John A. , Petersen, Bret T. , Vege, Santhi Swaroop , Kerbage, Anthony , AbiMansour, Jad P. , Vargas, Eric J. , Storm, Andrew C. , Chandrasekhara, Vinay , Petersen, Bret T. , Bazerbachi, Fateh , Majumder, Shounak , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S102-S103

10.14309/01.ajg.0001028912.11285.a9 Get It

S2096 Influence of Insulin Dosage on Type 2 Diabetes Remission After Metabolic and Bariatric Surgery: A Comparative Analysis of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
Salameh, Yara , Abboud, Donna Maria , Ghanem, Omar M. , Abboud, Donna M , Ghusn, Wissam , Salameh, Yara , Mosleh, Kamal Abi , Shah, Mithun V , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1497-S1498

10.14309/01.ajg.0001037752.22295.4b Get It

S1596 Comparison of Nutritional Parameters, Efficacy, and Safety of Endoscopic Gastrojejunostomy versus Duodenal Self-Expandable Metal Stent for the Management of Malignant Gastric Outlet Obstruction
Law, Ryan , Bofill-García, Aliana, Bauss, Jacob M. , AbiMansour, Jad P. , Siranart, Noppachai , Simadibrata, Daniel Martin , Storm, Andrew C. , Vargas, Eric J. , Dayyeh, Barham K. Abu , Chandrasekhara, Vinay

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1158-S1158

10.14309/01.ajg.0001035752.19015.60 Get It

S1575 Technique and Success Rate for Removal of a Novel Endoscopic Tack-and-Suture Device
Salameh, Yara , Lemke, Elizabeth, Aggarwal, Manik , Buttar, Navtej , Salameh, Yara , Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S1144-S1144

10.14309/01.ajg.0001035668.00026.21 Get It

S998 How Often Does Duodenal Bleeding Manifest as Blood in the Stomach? A Large Retrospective Series
Salameh, Yara , Sayegh, Lea, Aggarwal, Manik , Salameh, Yara , Sayegh, Lea, Storm, Andrew C.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S699-S700

10.14309/01.ajg.0001033360.16687.92 Get It

Utilization of an artificial intelligence–enhanced, web‐based application to review bile duct brushing cytologic specimens: A pilot study
Marya, Neil B. , Powers, Patrick, Bois, Melanie C. , Hartley, Christopher , Kerr, Sarah E. , Thangaiah, Judith Jebastin, Cantley, Richard , Gleeson, Ferga C. , Law, Ryan , Martin, John A. , Petersen, Bret T. , Levy, Michael J. , Jebastin, Judith A S , Cantley, Richard , Law, Ryan J, Maleki, Zahra , Pantanowitz, Liron , Petersen, Bret, Marya, Neil B. , Hartley, Christopher P , Norton, Daniel, Dayyeh, Barham K. Abu , Chandrasekhara, Vinay , Gores, Gregory J. , Maleki, Zahra , Petersen, Bret T. , Storm, Andrew C. , Graham, Rondell P.

Mayo Clinic

Cancer Cytopathology | August 29, 2024 | Volume: 132 | Issue: 12 | Pages: 779-787

10.1002/cncy.22898 | PMID 39207803 Get It

Abstract Background The authors previously developed an artificial intelligence (AI) to assist cytologists in the evaluation of digital whole‐slide images (WSIs) generated from bile duct brushing specimens. The aim of this trial was to assess the efficiency and accuracy of cytologists using a novel application with this AI tool. Methods Consecutive bile duct brushing WSIs from indeterminate strictures were obtained. A multidisciplinary panel reviewed all relevant information and provided a central interpretation for each WSI as being “positive,” “negative,” or “indeterminate.” The WSIs were then uploaded to the AI application. The AI scored each WSI as positive or negative for malignancy (i.e., computer‐aided diagnosis [CADx]). For each WSI, the AI prioritized cytologic tiles by the likelihood that malignant material was present in the tile. Via the AI, blinded cytologists reviewed all WSIs and provided interpretations (i.e., computer‐aided detection [CADe]). The diagnostic accuracies of the WSI evaluation via CADx, CADe, and the original clinical cytologic interpretation (official cytologic interpretation [OCI]) were compared. Results Of the 84 WSIs, 15 were positive, 42 were negative, and 27 were indeterminate after central review. The WSIs generated on average 141,950 tiles each. Cytologists using the AI evaluated 10.5 tiles per WSI before making an interpretation. Additionally, cytologists required an average of 84.1 s of total WSI evaluation. WSI interpretation accuracies for CADx (0.754; 95% CI, 0.622–0.859), CADe (0.807; 95% CI, 0.750–0.856), and OCI (0.807; 95% CI, 0.671–0.900) were similar. Conclusions This trial demonstrates that an AI application allows cytologists to perform a triaged review of WSIs while maintaining accuracy.
Using Pre-operative Insulin Dose to Predict Diabetes Remission After Roux-En-Y Gastric Bypass and Sleeve Gastrectomy
Salameh, Yara , Ghanem, Omar M. , Abi Mosleh, Kamal , Ghanem, Omar M , Ghusn, Wissam , Salameh, Yara , Mosleh, Kamal Abi , Shah, Mithun V , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Surgical Innovation | August 6, 2024 | Volume: 31 | Issue: 5 | Pages: 484-492

10.1177/15533506241273368 | PMID 39105388 Get It

Background Obesity is intricately associated with type-2 diabetes (T2D) and other cardiovascular conditions, increasing morbidity, mortality, and health care costs. Metabolic and bariatric surgeries (MBS) have shown promising results in significant weight loss and T2D remission, but existing predictive scores for post-MBS diabetes remission do not consider insulin dosage, potentially overlooking a critical factor. Methods A retrospective analysis of patients with T2D who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). The study focused on insulin dosage impact, divided into quartiles, on remission rates post-MBS. The effectiveness of RYGB vs SG was compared within insulin dose quartiles with up to 5 years of follow up. Results A total of 508 patients (64% female, 94.9% White, mean age 53.5 ± 10.5 years, BMI (46.0 ± 8.3 kg/m 2 ) were included in the analysis. This study demonstrates a profound association between insulin dosage quartiles and T2D remission after MBS. Patients with lower insulin requirements showed superior remission rates; those in the lowest quartile had remission rates of 73%, 70%, and 62% at 1, 3, and 5 years, respectively, compared to 34%, 37%, and 36% in the highest quartile ( P < 0.001 across all intervals). RYGB surgery showed a significantly better remission in the second and third insulin quartiles, suggesting its effectiveness over SG for patients with mid-range insulin requirements. Conclusion This study underscores the importance of considering insulin dosage when predicting T2D remission post-MBS. The findings advocate for a more nuanced selection of MBS procedures based on individual insulin profiles, potentially enhancing diabetes remission outcomes.